Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Silo Pharma Inc
(NQ:
SILO
)
0.9800
-0.0083 (-0.84%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Silo Pharma Inc
< Previous
1
2
3
4
5
Next >
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Regulatory Approval for Ketamine Implant, Moves Forward with Partner to Next Stage of Development
December 28, 2023
Via
Investor Brand Network
Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia
December 28, 2023
From
Silo Pharma, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Inks Exclusive License Agreement with Medspray Pharma BV
November 21, 2023
Via
Investor Brand Network
Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD
November 21, 2023
From
Silo Pharma, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Initiate Dose-Ranging Study, Positioning for Early Start of Phase 1 Clinical Trial of SPC-15
November 08, 2023
Via
Investor Brand Network
Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD
November 08, 2023
Study to determine therapeutic relevant dose range and pharmacokinetic to be used for first-in-human trial
From
Silo Pharma, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Positive Results of Preclinical Study to Advance SPU-21
October 16, 2023
Via
Investor Brand Network
Silo Pharma’s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis
October 16, 2023
From
Silo Pharma, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Initiates Human Factor Study of Its Targeted Prophylactic Treatment SPC-15
October 11, 2023
Via
Investor Brand Network
Silo Pharma Initiates Human Factor Study of SPC-15 for the Treatment of PTSD
October 11, 2023
From
Silo Pharma, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Reports Positive SPC-15 Data, Plans to File Pre-IND Application
September 20, 2023
Via
Investor Brand Network
Exposures
Product Safety
Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA
September 20, 2023
From
Silo Pharma, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Begin Feasibility Study of Proprietary Novel Intranasal Formulation for PTSD
September 12, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD
September 12, 2023
From
Silo Pharma, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Strategic Engagement to Step up IP and Patent Expansion Efforts
August 10, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Silo Pharma Engages Clarivate for Intellectual Property and Patent Management
August 10, 2023
From
Silo Pharma, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Significant Development Advancement of SPC-15
August 08, 2023
Via
Investor Brand Network
Silo Pharma Reaches Positive Milestone with Nasal Formulation of SPC-15 For Anxiety, PTSD, and Stress-Related Disorders
August 08, 2023
From
Silo Pharma, Inc.
Via
GlobeNewswire
BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Working to Deliver Novel Treatment for Chronic Pain Sufferers
June 23, 2023
Via
Investor Brand Network
Psychedelics Company Silo Pharma Working On Time-Release And Dosage Ketamine Implant And Topical, Hoping To Deliver Steady Pain Relief For Four Million Fibromyalgia Sufferers
June 23, 2023
Via
ACCESSWIRE
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Secures US Patent for SPU-21 Treatment for Autoimmune Disease
June 21, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Silo Pharma’s SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent
June 21, 2023
New patent expands Company’s intellectual property and technology rights portfolio
From
Silo Pharma, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Entry into Ketamine Implant Therapeutic Research Project
June 13, 2023
Via
Investor Brand Network
Silo Pharma Signs Agreement to Develop First-in-Class Ketamine Implant Therapeutic
June 13, 2023
From
Silo Pharma, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Participate, Share Profile on Webull Platform
June 02, 2023
Via
Investor Brand Network
Silo Pharma Announces Participation on Webull Corporate Communications Service Platform
June 02, 2023
From
Silo Pharma, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Agreement to Further Study Novel Joint Homing Peptide
May 30, 2023
Via
Investor Brand Network
Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21
May 30, 2023
From
Silo Pharma, Inc.
Via
GlobeNewswire
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’s Disease
May 09, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Global Alzheimer’s Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027
May 09, 2023
Palm Beach, FL – May 9, 2023 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is a progressive and neurodegenerative disorder that attacks the brain’s nerve cells or neurons, which...
Via
FinancialNewsMedia
Topics
Intellectual Property
Exposures
Intellectual Property
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.